Oxford Biomedica and Institut Mérieux enter into exclusive negotiations for the proposed acquisition of ABL Europe

Oxford Biomedica, a leading quality and innovation-led cell and gene therapy CDMO (“Contract Development Manufacturing Organisation”) and Institut Mérieux announce that they have entered into exclusive negotiations concerning Oxford Biomedica’s proposed acquisition of ABL Europe, a Group’s company specialized in … Continued

Institut Mérieux’s Press Release (november 2021)